Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome Daniela Romualdi, M.D., Maddalena Giuliani, M.D., Gaetano Draisci, M.D., Barbara Costantini, M.D., Francesca Cristello, M.D., Antonio Lanzone, M.D., Maurizio Guido, M.D., Ph.D. Fertility and Sterility Volume 88, Issue 1, Pages 131-138 (July 2007) DOI: 10.1016/j.fertnstert.2006.11.076 Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions
FIGURE 1 ACTH and cortisol response to the CRF test in PCOS women before (squares/solid bars) and after (circles/clear bars) 4 months of pioglitazone therapy. Left panel: curves of secretion. Right panel: AUC values. Romualdi. HPA-axis in PCOS: effect of pioglitazone. Fertil Steril 2007. Fertility and Sterility 2007 88, 131-138DOI: (10.1016/j.fertnstert.2006.11.076) Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions
FIGURE 2 Response to the CRF test in terms of A and P in PCOS women before (squares/solid bars) and after (circles/clear bars) treatment with pioglitazone. Left panel: curves of secretion. Right panel: AUC values. *P<.05 post-treatment vs. pre-treatment; **P<.01 post-treatment vs. pre-treatment. Romualdi. HPA-axis in PCOS: effect of pioglitazone. Fertil Steril 2007. Fertility and Sterility 2007 88, 131-138DOI: (10.1016/j.fertnstert.2006.11.076) Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions